Full Coverage

Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet

ad-hoc-news.de
May 16, 2008
        
Story Timeline:  200 days

Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide TabletRALEIGH, N.C.NC-SALIX-PHARMACEUTICALS Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has received an... [read full story]                    

Add Comment
Latest article on this story:

Salix shares slide after FDA requests more data on drug

 pharmiweb.co.uk May 19, 2008
First article on this story:

Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet

 finanzen.net May 17, 2008
Selected publications with coverage of this story:
redorbit.com yahoo.com finanzen.net ad-hoc-news.de euroinvestor.co.uk pharmiweb.co.uk newsobserver.com finanznachrichten.de
RELATED
Found 7 documents:

Salix Receives Approvable Letter for Ulcerative Colitis Drug

redorbit.com
May 19, 2008
        

Posted on: Monday, 19 May 2008, 12:00 CDT Salix Pharmaceuticals has received an approvable letter from the FDA for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older. Bill Forbes, vice president of R&D and chief development...

FDA asks for details on Salix drug

newsobserver.com
May 19, 2008
        

Oil prices gain while pump prices rise to new high FDA asks for details on Salix drug By Sabine Vollmer, Staff Writer A gastrointestinal drug that could have bolstered Salix Pharmaceuticals' sales has come up short of regulatory approval. The balsalazide tablet is a stronger version of Colazal,...

Salix shares slide after FDA requests more data on drug (at bizjournals.com)

yahoo.com
May 19, 2008
        

slipped Monday after it was revealed that U.S. drug regulators want more information on one of the company's drugs before they will consider approving it for sale. Salix (Nasdaq: SLXP), the Raleigh pharmaceutical company, said late on May 16 that it has received an "approvable letter" from the...

Salix Pharmaceuticals Receives Approvable Letter From FDA for Balsalazide Tablet

redorbit.com
May 17, 2008
        

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.

Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet (Business Wire)

yahoo.com
May 17, 2008
        

RALEIGH, N.C.----Salix Pharmaceuticals, Ltd. today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.

Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet

finanznachrichten.de
May 17, 2008
        

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older. “Late this...

Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet

finanzen.net
May 17, 2008
        

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older. "Late this...